The clinical management of non-alcoholic steatohepatitis (NASH) has entered a transformative era with the regulatory approval of Rezdiffra (resmetirom) by Madrigal Pharmaceuticals, representing a paradigm shift in specialized liver disease treatment. This innovative pharmaceutical achievement stands as the inaugural FDA-sanctioned medication specifically engineered to address NASH with...